GlassScriptPhysician profile
Cara Maria Fleming
NPI 1245851211
$3,230.12
in general payments reported to CMS, 2019-2025
20 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,447 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $424.89 | 2024-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $397.64 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $394.86 | 2024-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $326.15 | 2024-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $269.81 | 2024-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $266.40 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $199.23 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $182.11 | 2024-2025 | Fanapt |
| Abbvie INC. | $158.33 | 2024-2025 | |
| Lundbeck LLC | $146.42 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $116.82 | 2024 | |
| Sage Therapeutics, LLC | $81.10 | 2024-2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $63.63 | 2025 | Auvelity |
| Tris Pharma INC | $50.85 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $34.07 | 2025 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.02 | 2024-2025 | |
| Almatica Pharma LLC | $28.24 | 2024-2025 | Loreev Xr |
| Mirum Pharmaceuticals, INC. | $24.28 | 2025 | Cholbam |
| Takeda Pharmaceuticals U.S.A., INC. | $16.71 | 2024 | Trintellix |
| Neuronetics, INC. | $15.56 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.